The polycythemia-inducing strain of Friend virus (FV-P) causes a multistage erythroleukemia in susceptible mice. FV-P is a complex of two viruses, a replication-competent virus [Friend murine leukemia virus (F-MuLV)] and a replication-defective spleen focus-forming virus (SFFVp). We have addressed directly the role of SFFVp in the induction of the early stages of Friend disease by constructing stocks of SFFVp free of detectable F-MuLV, using a recently described retroviral helper-cell line. These preparations are capable of inducing erythroid bursts (vBFU-E) whose inducibility, kinetics, and responsiveness to erythropoietin suggest that they are very similar, if not identical, to the vBFU-E induced by FV-P. Single
iijections of helper-free SFFVp had no apparent effects in vivo, although the addition ofexogenous helper virus to the inoculum resulted in the induction of classic Friend disease. Increasing the effective titer by giving mice five daily virus injections resulted in the induction of splenomegaly and a large increase in the number of erythroid colony-forming units that were independent of erythropoietin. When the injections were discontinued, the spleens regressed and all the mice survived.
When the injections were continued, all the mice died within 25 days of the first injection. These results demonstrate that SFFVp alone can alter the growth characteristics of erythroid progenitors and is directly responsible for the induction of vBFU-E in vitro and the erythroid hyperplasia in vivo. They also demonstrate that the initial polyclonal stage of Friend disease is reversible and can be reproduced by using preparations of SFFVp free of detectable F-MuLV.
The polycythemia-inducing strain of Friend leukemia virus (FV-P) is a murine retrovirus complex that is capable of causing a multistage erythroleukemia in susceptible mice (1) (2) (3) (4) . The early stages of FV-P-induced disease are characterized by rapid and dramatic increases in erythrocyte production. In vivo manifestations of the erythroproliferative effects induced by this virus complex include macroscopic spleen foci, erythroid hyperplasia in spleen and marrow, hepatosplenomegaly, and polycythemia. Expansion of the erythroid precursor compartment is also evident from the large increase in the number of cells capable of forming small erythroid colonies (CFU-E) in semisolid cultures in vitro (5, 6) . These virus-infected cells appear to have a greatly reduced or no requirement for erythropoietin (EPO), the major hormone that governs erythropoiesis (7) .
These erythroproliferative effects can be reproduced and analyzed in culture as well. Direct infection of hemopoietic cells in vitro conveys altered growth characteristics to erythroid progenitors, resulting in the appearance of erythroid colonies (vBFU-E) after 5 days of culture in methylcellulose (8) (9) (10) . As with the precursors infected in vivo, the erythroid cells infected in vitro proliferate and differentiate without added EPO (11, 12) . Although these virus-infected cells exhibit a growth advantage compared to normal erythroid precursors, their proliferative capacity is limited and they are unable to form tumors in appropriate hosts.
In contrast, the later stages of Friend disease are characterized by the presence of transplantable, immortal erythroleukemia cells that can be detected by their ability to produce tumors in syngeneic hosts (13) (14) (15) (16) , spleen colonies in mutant SJ/Sid mice (17) , or large colonies of relatively undifferentiated cells in methylcellulose within 14 days after plating (18, 19) . The development of clonogenic assays for cells in both the preleukemic and leukemic stages of this disease make the Friend system an excellent model for analysis of multistage malignancies.
FV-P is actually a complex of two viruses: a replicationcompetent helper virus [Friend murine leukemia virus (FMuLV)] and a replication-defective spleen focus-forming virus (SFFVp). Molecular cloning (20, 21) and sequence analysis (22) (23) (24) has demonstrated that the SFFVp genome arose as the result of a recombination event between ecotropic and mink cell focus-inducing (MCF)-like viral env sequences (25) . The 3' end of the SFFVp genome encodes an env gene-related fusion glycoprotein gpS5 (22) (23) (24) that has been implicated in the early stages of Friend leukemia (26) (27) (28) .
There is much circumstantial evidence suggesting that it is the SFFVp component of FV-P that plays the major role in inducing erythroid hyperplasia during the early stages of Friend disease. For instance, the characteristics of the early stages induced in vivo and the erythroid bursts induced in vitro by the two strains of Friend virus (FV-A and FV-P) are independent of the MuLV helper used (29) (30) (31) . In addition, the number of vBFU-E induced in vitro is proportional to the titer of SFFVp (32) . Third, kinetics studies in vivo (33) and in vitro (32) MATERIALS AND METHODS SFFVp Plasmids. The plasmid pSFFVp has been described previously (28) . Plasmid pSV5neo-SFFVp was constructed by ligating gel-purified SFFVp fragment with EcoRI-digested pSV5neo, transforming bacteria, and screening for the recombinant by using standard techniques (35) .
Cells and Viruses. f-2 cells were kindly provided by R. Mulligan (Massachusetts Institute of Technology, Boston).
Standard O-SFFVp cells were generated by cotransfecting 2.5 jig of pSFFVp with 100 ng of pSV2neo (36) into q-2 cells via calcium phosphate-mediated gene transfer (37) . Transfectants were selected in the presence of the antibiotic G418 (GIBCO) at 400 ,ug/ml and pooled. High-titer q-SFFVp cells were generated by transfecting 100 ng of pSV5neo-SFFVp into 4i-2 cells and selecting for G418-resistant transformants. Virus stocks were obtained from slightly subconfluent cultures whose medium had been changed 16-24 hr before. Culture fluids were collected, filtered through 0.45-,um-pore filters, and kept on ice until use.
Freshly harvested virus stocks were used throughout.
vBFU-E and CFU-E Assays. The vBFU-E assay was performed essentially as described (11) . First 2.5 x 106 bone marrow cells from phenylhydrazine-treated NIH Swiss mice (4-6 weeks old) were mixed with 0.375 ml of appropriately diluted helper-free virus and incubated at 4°C for 2 hr. Then 2.125 ml of methylcellulose mix (containing 0.8% methylcellulose, 30% fetal calf serum, 1% bovine serum albumin, 0.1 mM thioglycerol, and antibiotics) was added and the mixture was dispensed into Costar 24-well cluster plates at 0.5 ml per well. The final concentration was 106 cells per ml. EPO, when added, was at a final concentration of 0.1 unit/ml unless otherwise noted. The cultures were incubated for 5 days at 37°C in an atmosphere of 95% air/5% CO2. Clusters of erythroid colonies (bursts) were scored in situ or after the cultures were clotted and stained with benzidine (38) . CFU-E were assayed in the plasma clot assay of Stephenson et al. (39) .
Mice. Adult NIH Swiss mice (4-6 weeks old) were maintained at the animal breeding facilities at the National Institutes of Health. Adult DBA/2J mice were obtained from The Jackson Laboratory. Phenylhydrazine treatment consisted of three intraperitoneal injections at -64, -48, and -40 hr with 40 ,ug/g of body weight in a volume of 0.2 ml.
RESULTS
Generation of Helper-Free Stocks of SFFVp. Recently, Mann et al. (34) described the construction of a cell line (q-2) containing a defective retroviral provirus that, although capable ofdirecting production of all the trans-acting proteins required for virus packaging, is itself unable to be packaged. From these cells, two lines producing helper-free SFFVp were generated. The first was generated by introducing the plasmid pSFFVp, which contains a complete infectious form of the SFFVp genome, into /-2 cells by using the cotransfection technique. The second cell line was generated by transfecting the plasmid pSV5neo-SFFVp into ,-2 cells. This plasmid contains the entire SFFVp genome, the dominant selectable neo gene, and the entire early region of polyoma virus (Fig. 1) Fig. 2 , burst appearance was maximal around day 5, with the earliest bursts appearing 3 days after infection and the latest appearing 8 days after infection. The majority ofthe virus-induced bursts contained 500-10,000 erythroblasts on day 5 . It was estimated that 70-100%o of the erythroblasts contained hemoglobin, as judged by their red coloration and their reactivity with benzidine (data not shown). Their size, morphology, time of appearance, and percent hemoglobinpositive cells resembled the published characteristics of the vBFU-E induced by FV-P (8) as opposed to those induced by FV-A or several other oncogene-containing retroviruses (unpublished data).
The induction of5-day vBFU-E by helper-free SFFVp was linear with the amount of virus added (Fig. 3) . Previous kinetics experiments suggested that erythroid burst induction required only a single event and that virus replication was not essential for burst formation (32) . The results presented here provide direct experimental support for this hypothesis.
It has previously been reported that the addition of EPO to the plasma clot cultures potentiates vBFU-E induction by FV-P (11, 12) . As shown in Fig. 4 , the induction of vBFU-E by helper-free SFFVp can be potentiated by even very low amounts of the hormone as well. As has been suggested previously (12) , this may indicate that the function of SFFVp infection is to make cells extremely sensitive to low amounts of EPO rather than make them completely independent. Taken together, these results suggest that the vBFU-E induced by our SFFVp mixed with helper virus died within 50 days of inoculation, whereas all of the mice that received only medium survived. In the mice that received five daily injections of helper-free SFFVp, we observed a large increase in spleen weight (Table 2) . However, despite the presence of enlarged spleens, none of the mice that received the five inoculations died within 60 days of the first injection. In addition, all of the spleens regressed to normal size.
After the first five daily injections, a second group of mice continued receiving virus injections once every 2 days. In contrast to the mice that received only five inoculations, all of these mice died within 25 days of the first inoculation (Fig.  5) . Microscopic examination of touch preparations of their enlarged spleens at autopsy revealed extreme erythroid hyperplasia.
Appearance of EPO-Independent CFU-E. The appearance of EPO-independent CFU-E in vivo is characteristic of FV-P infection (5, 6) . To assay for these cells, we prepared a single-cell suspension from a spleen fragment obtained from mice that had received five daily inoculations and incubated them in the CFU-E plasma clot assay as described (39 [40] [41] [42] . This observation, plus the rapidity of the induction of lethality in mice receiving continued injections of helper-free SFFVp, prompted us to look for the possible presence of contaminating helper virus in our virus preparations. Several experimental protocols were used to look for helper virus.
First, supernatants from qi-2 helper cells producing helperfree SFFVp were used to infect NIH/3T3 cells, which were then passaged to allow possible amplification of low levels of replication-competent helper 'virus. These cells were then assayed in the XC plaque assay' (43) . No helper virus was detected. Second, the spleens from DBA/2J mice that had received multiple injections of helper-free SFFVp were observed for the presence of leukemia. Although their spleens increased in size after 5-10 injections, discontinuation of the injections resulted in regression of'spleen size and survival in the large majority (29/30) of the mice. The spleen of one mouse did not regress, however. In this mouse, ecotropic helper virus was detected by cocultivation of the spleen cells with NIH/3T3 cells followed by the XC assay. The presence of helper virus in this one mouse may have been due to a very low level of release of replication-competent virus from the helper cells. Alternatively, it may have represented activation of the endogenous DBA/2J provirus present in preleukemic spleen cells. Finally, the observations that multiple injections in phenylhydrazine-treated NIH Swiss mice were required to observe lethality and that the spleens of these mice regressed when daily virus injections were discontinued suggest that the supernatants from 4--2 cells transfected with pSV5neo-SFFVp did not contain significant, if any, titers of helper virus.
DISCUSSION
The results described here demonstrate that preparations of the polycythemia-inducing strain of Friend spleen focusforming virus (SFFVp), free of any detectable helper virus, are capable of inducing all of the cellular events associated with the early stages of Friend leukemia. These cellular changes include the induction oferythroid bursts after in vitro infection, splenomegaly, a large increase in the number of CFU-E whose requirements for EPO were either greatly reduced or abolished, and lethality in 100% of the mice. To observe the effects of helper-free SFFVp in vivo, it was necessary to obtain high titers of SFFVp by using a plasmid vector containing the SFFVp genome and capable of extrachromosomal replication in mouse cells. In addition, treatment with phenylhydrazine and multiple injections of virus were required to observe these in vivo effects. Discontinuing virus injections in mice that had enlarged spleens resulted in complete regression of the disease. Taken together, these observations provide direct evidence that the SFFVp component of FV-P is responsible for all the early erythroid transformation events associated with Friend leukemia.
It is ofinterest to note that the spleens of mice infected with helper-free SFFVp contained very high numbers of EPOindependent CFU-E, even higher than the levels observed in control mice infected with FV-P (SFFVp + F-MuLV). This observation likely reflects the greater effective dose of SFFVp delivered to the mice receiving multiple injections of virus. It The early stages of FV-P-induced leukemia are characterized by the polyclonal proliferation of erythroid target cells with very limited proliferative capacity. The relatively long latency of FV-P-induced leukemia (18, 19, 44) and the reversibility of the erythroid hyperplasia induced by helperfree SFFVp observed here suggests that subsequent genetic events are required for the emergence of truly leukemic cell clones. Indeed, tumorigenic transformation late after infection appears to be a relatively rare event, as demonstrated by studies on the unique rearrangements of the cellular p53 gene observed in tumor cell lines derived from Friend virusinfected mice (45) and by the presence of common sites of integration of F-MuLV in independent clones isolated from the same leukemic spleens (unpublished observations).
Although the experiments described here demonstrate that infection with SFFVp'is sufficient to induce the early stages of Friend leukemia, the roles of both SFFVp and its helper virus in the later stages of the disease remain to be elucidated. As with other chronic virally induced leukemias (46) , the viral components of FV-P may play a direct role in these events. Alternatively, their function may simply be to' expand the target cell population in which subsequent transformation events can occur. The helper-free preparations of SFFVp described here will allow us to assess more definitively the role of each of the viral components of FV-P in the later stages of the disease and the molecular events associated with them.
Note Added in Proof. Recently Wolff and Ruscetti (47) reported the generation and characterization of helper-free SFFVp. In contrast to the results presented here, they found that a single injection of helper-free SFFVp was sufficient to induce spleen foci and splenomegaly.
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